CA2560035A1 - Control of feeding behavior by changing neuronal energy balance - Google Patents

Control of feeding behavior by changing neuronal energy balance Download PDF

Info

Publication number
CA2560035A1
CA2560035A1 CA002560035A CA2560035A CA2560035A1 CA 2560035 A1 CA2560035 A1 CA 2560035A1 CA 002560035 A CA002560035 A CA 002560035A CA 2560035 A CA2560035 A CA 2560035A CA 2560035 A1 CA2560035 A1 CA 2560035A1
Authority
CA
Canada
Prior art keywords
ampk
subject
compound
food intake
aicar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002560035A
Other languages
English (en)
French (fr)
Inventor
Gabriele V. Ronnett
Francis P. Kuhajda
Jagan N. Thupari
Leslie E. Landree
Timothy H. Moran
Eun-Kyoung Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Fasgen LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2560035A1 publication Critical patent/CA2560035A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002560035A 2004-03-18 2005-03-18 Control of feeding behavior by changing neuronal energy balance Abandoned CA2560035A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55422804P 2004-03-18 2004-03-18
US60/554,228 2004-03-18
PCT/US2005/009069 WO2005089773A1 (en) 2004-03-18 2005-03-18 Control of feeding behavior by changing neuronal energy balance

Publications (1)

Publication Number Publication Date
CA2560035A1 true CA2560035A1 (en) 2005-09-29

Family

ID=34993435

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002560035A Abandoned CA2560035A1 (en) 2004-03-18 2005-03-18 Control of feeding behavior by changing neuronal energy balance

Country Status (6)

Country Link
US (1) US20080119548A1 (enExample)
EP (1) EP1732572A4 (enExample)
JP (1) JP2007529549A (enExample)
AU (1) AU2005222707B2 (enExample)
CA (1) CA2560035A1 (enExample)
WO (1) WO2005089773A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100016016A (ko) * 2007-03-30 2010-02-12 산토리 홀딩스 가부시키가이샤 교감 신경 활동 항진 작용을 갖는 의약 조성물 또는 음식물
JP5807919B2 (ja) * 2013-07-31 2015-11-10 大学共同利用機関法人自然科学研究機構 糖尿病による代謝異常を改善するための組成物
BR112024002354A2 (pt) * 2021-08-06 2024-04-30 Centre Nat Rech Scient Populações de pequenas vesículas extracelulares para uso no tratamento de obesidade
EP4137148A1 (en) * 2021-08-17 2023-02-22 Universidade de Santiago de Compostela Small extracellular vesicles expressing a dominant negative ampk alpha 1 mutant for use in the treatment of obesity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
WO2001010449A1 (en) * 1999-08-09 2001-02-15 Trustees Of Boston University Method of maintaining vascular integrity using aicar (5-amino-4-imidazole riboside) and related compounds
KR20030016228A (ko) * 2000-02-16 2003-02-26 존스 홉킨스 유니버시티 스쿨 오브 메디슨 신경펩티드 ｙ 농도의 감소에 의해 유도되는 체중 감량
WO2001093873A1 (en) * 2000-06-06 2001-12-13 Trustees Of Boston University Use of aicar and related compounds
WO2002009726A1 (en) * 2000-07-31 2002-02-07 Trustees Of Boston University Methods of treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds
US20030212013A1 (en) * 2001-06-14 2003-11-13 Winder William W Use of amp kinase activators for treatment type 2 diabetes and insulin resistance
US20050143467A1 (en) * 2002-02-08 2005-06-30 The Johns Hopkins University School Of Medicine Licensing And Technology Development Stimulation of cpt-1 as a means to reduce weight

Also Published As

Publication number Publication date
AU2005222707B2 (en) 2010-06-17
US20080119548A1 (en) 2008-05-22
AU2005222707A1 (en) 2005-09-29
EP1732572A4 (en) 2007-04-18
JP2007529549A (ja) 2007-10-25
EP1732572A1 (en) 2006-12-20
WO2005089773A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
Landree et al. C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism
Buler et al. SIRT5 is under the control of PGC‐1α and AMPK and is involved in regulation of mitochondrial energy metabolism
Aatsinki et al. Metformin induces PGC‐1α expression and selectively affects hepatic PGC‐1α functions
Meur et al. Tonic activation of NMDA receptors by ambient glutamate of non‐synaptic origin in the rat hippocampus
CA2339218C (en) Methods and compositions for increasing insulin sensitivity
AU2013266086B2 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
US7022484B2 (en) Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
Nystrom et al. Sepsis and AMPK activation by AICAR differentially regulate FoxO-1,-3 and-4 mRNA in striated muscle
Rewal et al. Alpha4 subunit‐containing GABAA receptors in the accumbens shell contribute to the reinforcing effects of alcohol
Pil Hwang et al. 3‐Caffeoyl, 4‐dihydrocaffeoylquinic acid from S alicornia herbacea attenuates high glucose‐induced hepatic lipogenesis in human H ep G 2 cells through activation of the liver kinase B 1 and silent information regulator T 1/AMPK‐dependent pathway
Liu et al. Quercetin oppositely regulates insulin‐mediated glucose disposal in skeletal muscle under normal and inflammatory conditions: The dual roles of AMPK activation
Oguri et al. Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism
Gess et al. Sodium‐dependent vitamin C transporter 2 (SVCT2) is necessary for the uptake of L‐ascorbic acid into Schwann cells
Dadon-Freiberg et al. REV-ERBα alters circadian rhythms by modulating mTOR signaling
EP2408906A1 (en) Methods for modulating metabolic and circadian rhythms
AU2005222707B2 (en) Control of feeding behavior by changing neuronal energy balance
Pei‐Yuan et al. Overexpression of Axl reverses endothelial cells dysfunction in high glucose and hypoxia
Sergeeva et al. GABAA‐receptor modification in taurine transporter knockout mice causes striatal disinhibition
Nho et al. β1-Integrin-collagen interaction suppresses FoxO3a by the coordination of Akt and PP2A
Li et al. d-Glucosamine induces circadian phase delay by promoting BMAL1 degradation through AMPK/mTOR pathway
Forget et al. Impact of basic FGF expression in astrocytes on dopamine neuron synaptic function and development
Salgado et al. GKRP-dependent modulation of feeding behavior by tanycyte-released monocarboxylates
Piggins et al. Intercellular interactions and the physiology of circadian rhythms in mammals
Yang et al. Isoprenylcysteine carboxyl methyltransferase inhibitors exerts anti-inflammatory activity
Suzuki et al. Na+, K+-ATPase activity is inhibited in cultured intestinal epithelial cells by endotoxin or nitric oxide

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued